The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.A. Inoue, T. Nukiwa, Keigo Kobayashi et al.|Journal of Clinical Oncology|2010Cited by 1